Fluorinated natural products with clinical significance

Current Topics in Medicinal Chemistry

Volumn 6, Issue 14, 2006, Pages 1529-1543

  Thomas, Craig J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Artemisinin; Campothecin; Epothilones; Fluorine; Natural products; Taxanes; Vinca alkaloids

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEETHER; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; ARTEMISININ DERIVATIVE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CHLOROQUINE; CIPROFLOXACIN; DE 310; DIFLOMOTECAN; EPOTHILONE DERIVATIVE; ESSENTIAL OIL; EXATECAN; FLUDROCORTISONE; FLUORINE; FLUOROACETIC ACID; FLUOROCITRIC ACID; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOXETINE; IRINOTECAN; NATURAL PRODUCT; NAVELBINE; PLATINUM; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCA ALKALOID;

ANTIFUNGAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTEMISIA ANNUA; CAMPTOTHECA; CATHARANTHUS ROSEUS; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CLINICAL STUDY; CLINICAL TRIAL; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; FLUORINATION; HUMAN; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MEDICINAL PLANT; MOLECULAR INTERACTION; MYCOBACTERIUM; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SUBSTITUTION REACTION;

BIOLOGICAL PRODUCTS; FLUORIDES; FLUORINE; HYDROCARBONS, FLUORINATED; MOLECULAR STRUCTURE; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 33746611885     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606777951109     Document Type: Review

References (133)

1. O'Hagan, D. Harper, D. B. Fluorine-containing natural products. J. Fluor. Chem. 1999, 100, 127-133.
2. Wedepohl, K. H. The composition of the continental crust. Geochimica et Cosmochimica Acta. 1995, 59, 1217-1232.
3. Zechel, D. L.; Reid, S. P.; Nashiru, O.; Mayer, C.; Stoll, D.; Jakeman, D. L.; Warren, R. A. J.; Withers, S. G. Enzymatic Synthesis of Carbon-Fluorine Bonds. J. Am. Chem. Soc. 2001, 123, 4350-4351.
4. N2 Reaction Mechanism. ChemBioChem 2004, 5, 685-690.
5. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry. ChemBioChem 2004, 5, 637-643.
6. Maienfisch, P.; Hall, R. G. The Importance of Fluorine in the Life Science Industry. Chimia 2004, 58, 93-99.
7. Marais, J. S. C. Onderstepoort. J. Vet. Sci. Anim. Ind. 1943, 18, 203.
8. Fried, J.; Sabo, E. F. 9α-Fluoro Derivatives of Cortisone and Hydrocortisone. J. Am. Chem. Soc. 1954, 76, 1455-1456.
9. Heidelberg, C.; Chaudhuari, N. K.; Danenberg, P.; Mooren, D.; Griesback, L.; Duschinsky, R.; Schnitzer, R. J.; Pleven, E.; Scheiner, J. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature, 1957, 179, 663-666.
10. Dunitz, J. D. Organic Fluorine: Odd Man Out. ChemBioChem 2004, 5, 614-621.
11. Biffinger, J. C.; Kim, H. W.; DiMagno, S. G. The Polar Hydrophobicity of Fluorinated Compounds. ChemBioChem 2004, 5, 622-627.
12. Fan, Y.; Shi, L. M.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Quantitative Structure-Antitumor Activity Relationships of Camptothecin Analogues: Cluster Analysis and Genetic Algorithm-Based Studies. J. Med. Chem. 2001, 44, 3254-3263.
13. Leeson, P. D.; Davis, A. M. Time-Related Differences in the Physical Property Profiles of Oral Drugs. J. Med. Chem. 2004, 47, 6338-6348.
14. Gerebtzoff, G.; Li-Glatter, X.; Fisher, H.; Frentzel, A.; Seelig, A. Halogenation of Drugs Enhances Membrane Binding and Permeation. ChemBioChem 2004, 5, 676-684.
15. Edwards, P. N. Uses of Fluorine in Chemotherapy. In Organo-fluorine Chemistry: Principles and Commercial Applications, Eds Banks, R. E.; Smart B. E.; Tatlow J. C. Plenum Press, New York, 1994, 501-542.
16. Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of Fluorine-Containing Drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 443-470.
17. Hutchinson, I.; Chua, M. S.; Browne, H. L.; Trapani, V.; Bradshaw, T. D.; Westwell, A. D.; Stevens, M. F. G. Antitumor Benzothiazoles 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J. Med. Chem. 2001, 44, 1446-1455.
18. Kuhnert, N. Hundredth Anniversary of Aspirin. Chemie in Unserer Zeit 1999, 33, 213-220.
19. Murphy, C. D.; Schaffrath, C.; O'Hagan, D. O. Fluorinated natural products: the biosynthesis of fluoroacetate and 4-fluorothreonine in Streptomyces cattleya. Chemosphere 2003, 52, 455-461.
20. Xu, X-H.; Yao, G.-M.; Li, Y.-M.; Lu, J.-H.; Lin, C.-J.; Wang, X.; Kong, C.-H. 5-Fluorouracil Derivatives from the Sponge Phakellia fusca. J. Nat. Prod. 2003, 66, 285-288.
21. Kim, C.; Haddad, J.; Vakulenko, S. B.; Meroueh, S. O.; Wu, Y.; Yan, H.; Mobashery, S. Fluorinated Aminoglycosides and their Mechanistic Implication for Aminoglycoside 3′-Phosphotransferases from Gram-Negative Bacteria. Biochemistry 2004, 43, 2373-2383.
22. Kaneko, S.; Nakajima, N.; Shikano, M.; Katoh, T.; Terashima, S. Synthetic Studies of Huperazine A and its Fluorinated Analogues. 2. Synthesis and Acetylcholinesterase Inhibitory Activity of Novel Fluorinated Huperazine A Analogues. Tetrahedron 1998, 54, 5485-5506.
23. Ambrosi, P.; Arnone, A.; Bravo, P.; Bruché, L.; De Cristofaro, A.; Francardi, V.; Frigerio, M.; Gatti, E.; Germinara, G. S.; Panzeri, W.; Pennacchio, F.; Pesenti, C.; Rotundo, G.; Roversi, P. F.; Salvadori, C.; Viani, F.; Zanda, M. Stereoselective Synthesis of Trifluoro- and Monofluoro-Analogues of Frontalin and Evaluation of their Biological Activity. J. Org. Chem. 2001, 66, 8336-8343.
24. Sutherland, A.; Gallagher, T.; Sharples, C. G. V.; Wonnacott, S. Synthesis of Two Fluoro Analogues of the Nicontinic Acetylcholine Receptor Agonist UB-165. J. Org. Chem. 2003, 68, 2475-2478.
25. Biscardi, M.; Caporale, R.; Pagliai, G.; Leoni, F.; Bernabei, P.; Santini, V.; Ciolli, S.; Grossi, A. In vitro antileukemic effect of a new anthracycline analogue, MEN 11079. Leukemia Res. 2003, 27, 1125-1134.
26. Diederich, S.; Hanke, B.; Burkhardt, P.; Müller, M.; Schöneshöfer, M.; Bähr, V.; Oelkers, W. Metabolism of synthetic corticosteroids by 11β-hydroxysteroid-dehydrogenases in man. Steroids 1998, 63, 271-277.
27. 2α. J. Med. Chem. 1980, 23, 1077-1083.
28. 19F-NMR Studies and Biological Activity. Chem. Pharm. Bull. 2002, 50, 475-483.
29. Goss, R. J. M.; Hong, H. A novel fluorinated erythromycin antibiotic. Chem. Commun. 2005, 3983-3985.
30. Shimizu, M.; Hiyama, T. Modern Synthetic Methods for Fluorine-Substituted Target Molecules. Angew. Chem. Int. Ed. 2005, 44, 214-231.
31. Ma, J.-A.; Cahard, D. Asymmetric Fluorination, Trifluoromethylation, and Perfluoroalkylation Reactions. Chem. Rev. 2004, 104, 6119-6146.
32. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
33. Hsiang, Y.-H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260, 14873-14878.
34. Du, W. Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron 2003, 59, 8649-8687.
35. Thomas, C. J.; Rahier, N. J.; Hecht, S. M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12, 1585-1604.
36. Garcia-Carbonero, R.; Supko, J. G. Currrent Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Campthothecins. Clin. Cancer Res. 2002, 8, 641-661.
37. Lokiec, F.; Du Sorbier, B. M.; Sanderink, G.-J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res. 1996, 2, 1943-1949.
38. Li, K.; Chen, X.; Zhong, D.; Li, Y. Identification of the metabolites of 9-nitro-20(S)-Camptothecin in Rats. Drug Metab. Dispos. 2003, 31, 792-797.
39. Burke, T. G.; Mi, Z. Ethyl Substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of Human Serum Albumin. J. Med. Chem. 1993, 36, 2580-2582.
40. Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S.-M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32, 715-720.
41. Josien, H.; Bom. D.; Curran, D. P.; Zheng, Y.-H.; Chou, T.-C. 7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents. Bioorg. Med. Chem. Lett. 1997, 7, 3189-3194.
42. Lavergne, O.; Lesueur-Ginot, L.; Pla Rodas, F.; Bigg, D. C. H. BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. Lett. 1997, 7, 2235-2238.
43. Lackey, K.; Besterman, J. M.; Fletcher, W.; Leitner, P.; Morton, B.; Sternbach, D. D. Rigid Analogues of Camptothecin as DNA Topoisomerase I inhibitors. J. Med. Chem. 1995, 38, 906-911.
44. Lavergne, O.; Demarquay, D.; Bailly, C.; Lanco, C.; Rolland, A.; Huchet, M.; Coulomb, H.; Muller, N.; Baroggi, N.; Camara, J.; Le Breton, C.; Manginot, E.; Cazaux, J.-B.; Bigg, D. C. H. Topoisomerase I-Mediated Antiproliferative Activity of Enantiomerically Pure Fluorinated Homocamptothecins. J. Med. Chem. 2000, 43, 2285-2289.
45. Kasprzyk, P. G.; Carlson, M.; Lauer, J.; Demarquay, D.; Lessueur-Ginot, L. An E-ring modified camptothecin, BN 80915, shows unusual stability and high activity both in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 1999, 40, 739.
46. Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L; Lavergne, O.; Kasprzyk, P. G.; Bailly, C.; Camara, J.; Bigg, D. C. H. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anti-Cancer Drugs 2001, 12, 9-19.
47. Bates, S. E.; Medina-Pérez, W. Y.; Kohlhagen, G.; Antony, S.; Nadjem, T.; Robey, R. W.; Pommier, Y. ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins. J. Pharmacol. Exp. Ther. 2004, 310, 836-842.
48. Gelderblom, H.; Salazar, R.; Verweij, J.; Pentheroudakis, G.; de Jonge, M. J. A.; Devlin, M.; van Hooije, C.; Seguy, f.; Obach, R.; Pruñonosa, J.; Principe, P.; Twelves, C. Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors. Clin. Cancer Res. 2003, 9, 4101-4107.
49. Mitsui, I.; Kumazawa, E.; Hirota, Y.; Aonuma, M.; Sugimori, M.; Ohsuki, S.; Uoto, K.; Ejima, A.; Terasawa, H.; Sato, K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Japanese J. Cancer Res. 1995, 86, 776-782.
50. Joto, N.; Ishii, M.; Minami, M.; Kuga, H.; Mitsui, I.; Tohgo, A. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int. J. Cancer 1997, 72, 680-686.
51. Clamp, A.; Adams, M.; Atkinson, R.; Boven, E.; Calvert, A. H.; Cervantes, A.; Ganesan, T.; Lotz, J.; Vasey, P.; Cheverton, P.; Jayson, G. C. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol. Oncol. 2004, 95, 114-119.
52. Ajani, J. A.; Takimoto, C.; Becerra, C. R.; Silva, A.; Baez, L.; Cohn, A.; Major, P.; Kamida, M.; Feit, K.; De Jager, R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest. New Drugs 2005, 23, 479-484.
53. Soepenberg, O.; de Jonge, M. J. A.; Sparreboom, A.; de Bruin, P.; Eskens, F. A. L. M.; de Heus, G.; Wanders, J.; Cheverton, P.; Ducharme, M. P.; Verweij, J. Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2005, 11, 703-711.
54. Shibata, N.; Ishimaru, T.; Nakamura, M.; Toru, T. 20-Deoxy-20-fluorocamptothecin: Design and Synthesis of Camptothecin Isostere. Synlett 2004, 14, 2509-2512.
55. Tangirala, R. S.; Dixon, R.; Danzhou, Y.; Ambrus, A.; Antony, S.; Agama, K.; Pommier, Y.; Curran, D. P. Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin. Bioorg Med. Chem. Lett. 2005, 15, 4736-4740.
56. Lal, G. S.; Pez, G. P.; Syvret, R. G. Electrophilic NF Fluorinating Agents. Chem. Rev. 1996, 96, 1737-1755.
57. Singh, R. P.; Shreeve, J. M. Recent Advances in Nucleophilic Fluorination Reactions of Organic Compounds Using Deoxyfluor and DAST. Synthesis 2002, 17, 2561-2578.
58. Qinghaosu Antimalarial Coordinating Research Group. Antimalarial studies on qinghaosu. Chin. Med. J. 1979, 92, 811-816.
59. O'Neill, P. M.; Posner, G. H. A Medicinal Chemistry Perspective on Artemisinin and Related Endoperoxides. J. Med. Chem. 2004, 47, 2945-2964.
60. Hien, T. T.; White, N. J. Qinghaosu. The Lancet 1993 341, 603-608.
61. O'Neill, P. M. A Worthy Adversary for Malaria. Nature 2004, 430, 838-839.
62. Posner, G. H.; O'Neill, P. M. Knowledge of the Proposed Chemical Mechanism of Action and Cytochrome P450 Metabolism of Antimalarial Trioxanes like Artemisinin Allows Rational Design of new Antimalarial Peroxides. Acc. Chem. Res. 2004, 37, 397-404.
63. Maggs, J. L.; Bishop, L. P. D.; Edwards, G.; O'Neill, P. M.; Ward, S. A.; Winstanley, P. A.; Park, B. K. Biliary Metabolites of β-Artemether in Rats: Biotransformations of an Antimalarial Endoperoxide. Drug Metab. Dispos. 2000, 28, 209-217.
64. Abouabdellah, A.; Bégué, J.-P.; Bonnet-Delpon, D.; Gantier, J.-C.; Nga, T. T. T.; Thac, T. D. Synthesis and in vivo Antimalarial Activity of 12α-Trifluoromethyl-hydroartemisinin. Bioorg. Med. Chem. Lett. 1996, 6, 2717-2720.
65. 3-substituierten organyl(chlor)silane Tetrahedron Lett. 1984, 25, 2195-2198.
66. Magueur, G.; Crousee, B.; Charneau, S.; Grellier, P.; Bégué, J.-P.; Bonnet-Delpon, D. Fluoroartemisinin: Trifluoromethyl Analogues of Artemether and Artesunate. J. Med. Chem. 2004, 47, 2694-2699.
67. Hindley, S.; Ward, S. A.; Storr, R. C.; Searle, N. L.; Bray, P. G.; Park, B. K.; Davies, J.; O'Neill, P. M. Mechanism-Based Desgin of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of new Diamine Containing Analogues. J. Med. Chem. 2002, 45, 1052-1063.
68. Posner, G. H.; Cumming, J. N.; Woo, S.-H.; Ploypradith, P.; Xie, S.; Shapiro, T. A. Orally Active Antimalarial 3-Substituted Trioxanes: New Synthetic Methodology and Biology Evaluation. J. Med. Chem. 1998, 41, 940-951.
69. Posner, G. H.; Jeon, H. B.; Parker, M. H.; Krasavin, M.; Paik, I.-H.; Shapiro, T. A. Antimalarial Simplified 3-Aryltrioxanes: Synthesis and Preclinical Efficacy/Toxicity Testing in Rodents. J. Med. Chem. 2001, 44, 3054-3058.
70. Jaquet, C.; Stohler, H. R.; Chollet, J.; Peters, W. Antimalarial activity of the bicyclic peroxide Ro 42-1611 (arteflene) in experimental models. Trop. Med. Parasitol. 1994, 45, 266-271.
71. Bishop, L. P. D.; Maggs, J. L.; O'Neill, P. M.; Park, B. K. Metabolism of the Antimalarial Endoperoxide Ro 42-1611 (Arteflene) in the Rat: Evidence for Endoperoxide Bioactivation. J. Pharmacol. Exp. Ther. 1999, 289, 511-520.
72. Salako, L. A.; Guiguemde, R.; Mittelholzer, M.-L.; Haller, L.; Sorenson, F.; Sturchler, D. Ro 42-1611 in the treatment of patients with mild malaria: A clinical trial in Nigeria and Burkino Faso. Trop. Med. Parasitol. 1994, 45, 284-287.
73. Maggs, J. L.; Bishop, L. P. D.; Batty, K. T.; Dodd, C. C.; Ilett, K. F.; O'Niell, P. M.; Edwards, G.; Park, B. K. Chemico-Biological Interactions 2004, 147, 173-184.
74. Noble, R. L.; Beer, C. T.; Cutts, J. H. Role of Chance Observations in Chemotherapy: Vinca Rosea. Ann. N. Y. Acad. Sci. 1958, 76, 882-894.
75. Noble, R. L. The discovery of the Vinca alkaloids - chemotherapeutic agents against cancer. Biochem. Cell Biol. 1990, 68, 1344-1351.
76. Antitumor Bisindole Alkaloids from Catharanthus roseus (L.). The Alkaloids. Brossi, A.; Suffness, M.; Eds., Academic Press Inc.: San Diego, 1990; Vol. 37.
77. Wang, H.-K. Plant-derived anticancer agents currently in clinical use or in clinical trials. IDrugs 1998, 1, 92-102.
78. George, P.; Journey, L. J.; Goldstein, M. N. Effects of vincristine on the fine structure of HeLa cells during mitosis. J. Natn. Cancer Inst. 1965, 35, 355-361.
79. Himes, R. H. Interactions of the Catharanthus (Vinca) Alkaloids with Tubulin and Microtubules. Pharmacol. Ther. 1991, 51, 257-267.
80. Pellegrini, F.; Budman, D. R. Review: Tubulin Function, Action of Antitubulin Drugs, and new Drug Development. Cancer Invest. 2005, 23, 264-273.
81. Jordan, M. A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991, 51, 2212-2222.
82. Dhamodharan, R.; Jordan, M. A.; Thrower, D.; Wilson, L.; Wadsworth, P. Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol. Cell Biol. 1995, 6, 1215-1229.
83. Fahy, J. Modifications in the «upper» or Velbenamine Part of the Vinca Alkaloids have Major Implications for Tubulin Interacting Activities. Curr. Pharm. Design 2001, 7, 1181-1197.
84. Potier, P.; Langlois, N.; Langlois, Y.; Guéritte, F. Partial Synthesis of Vinblastine-type Alkaloids. J. Chem. Soc. Chem. Comm. 1975, 16, 670-671.
85. Langlois, N.; Guéritte, G.; Langlois, Y.; Potier, P. Application of a Modification of the Polonoviski reaction to the Synthesis of Vinblastine-Type Alkaloids. J. Am. Chem. Soc. 1976, 98, 7017-7024.
86. Fahy, J.; Duflos, A.; Ribet, J.-P.; Jacquesy, J.-C.; Berrier, C.; Jouannetaud, M.-P.; Zunino, F. Vinca Alkaloids in Superacid Media: A Method for Creating a New Family of Antitumor Derivatives. J. Am. Chem. Soc. 1997, 119, 8576-8577.
87. Olah, G. A. Superelectrophiles. Angew. Chem., Int. Ed. Engl. 1993, 32, 767-788.
88. Jacquesy, J.-C.; Berrier, C.; Jouannetaud, M.-P.; Zunino, F.; Fahy, J.; Duflos, A.; Ribet, J.-P. Fluorination in superacids: a novel access to biologically active compounds. J. Fluor. Chem. 2002, 114, 139-141.
89. Kruczynski, A.; Barret, J.-M.; Etiévant, C.; Colpaert, F.; Fahy, J.; Hill, B. T. Antimitotic and Tubulin-Interacting properties of Vinflunine, a Novel Fluorinated Vinca Alkaloid. Biochem. Pharmacol. 1998, 55, 635-648.
90. Ngan, V. K.; Bellman, K.; Panda, D.; Hill, B. T.; Jordan, M. A.; Wilson, L. Novel Actions of the Antitumor Drugs Vinflunine and Vinorelbine on Microtubules. Cancer Res. 2000, 60, 5045-5051.
91. Shnyder, S. D. Vinflunine. IDrugs 2004, 7, 851-859.
92. Etievant, C.; Barret, J.-M.; Kruczynski, A.; Perrin, D.; Hill, B. T. Vinfluinine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (PgP)-mediated multidrug resistance in vivo and in vitro. Invest. New Drugs 1998, 16, 3-17.
93. Holwell, S. E.; Hill, B. T.; Bibby, M. C. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer 2001, 84, 290-295.
94. Kingston, D. G. I. Taxol, a molecule for all seasons. Chem. Commun. 2001, 867-880.
95. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
96. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
97. Baloglu, E.; Kingstong, D. G. I. The Taxane Diterpenoids. J. Nat. Prod. 1999, 62, 1448-1472.
98. Jennewein, S.; Croteau, R. Taxol: biosynthesis, molecular genetics, and biotechnological applications. Appl. Microbiol. Biotechnol. 2001, 57, 13-19.
99. Fang, W.-S.; Liang, X.-T. Recent Progress in Structure Activity Relationship and Mechanistic Studies of Taxol Analogues. Mini-Rev. Med. Chem. 2005, 5, 1-12.
100. Guéritte-Voegelein, F.; Guénard, D.; Lavelle, F.; Le Goff, M.-T.; Mangatal. L.; Potier, P. Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity. J. Med. Chem. 1991, 34, 992-998.
101. Horwitz, S. B. Personal Recollections on the Early Development of Taxol. J. Nat. Prod. 2004, 67, 136-138.
102. I-S Cell Cycle Checkpoint Function Sensitizes Cells to Microtubule Inhibitor-induced Apoptosis. Cancer Res. 1999, 59, 3831-3837.
103. Blagosklonny, V. V.; Giannakakou, P.; El-Deiry, W. S.; Kingston, D. G. I.; Higgs, P. I.; Neckers, L.; Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997, 57, 130-135.
104. Monsarrat, B.; Mariel, E.; Cros, S.; Garés, M.; Guénard, D.; Guéritte-Voegelein, F.; Wright, M. Taxol Metabolism: Isolation and Identification of Three Major Metabolites of Taxol in Rat Bile. Drug Metab. Dispos. 1990, 18, 895-901.
105. Ojima, I. Use of Fluorine in the Medicinal Chemistry and Chemical Biology of Bioactive Compounds - A case Study of Fluorinated Taxane Anticancer Agents. ChemBioChem 2004, 5, 628-635.
106. Ojima, I.; Inoue, T.; Chakravarty, S. Enantiopure fluorine-containing taxoids: potent anticancer agents and versatile probes for biomedical problems. J. Fluor. Chem. 1999, 97, 3-10.
107. Ojima, I.; Lin, S.; Slater, J. C.; Wang, T.; Pera, P.; Bernacki, R. J.; Ferlini, C.; Scambia, G. Syntheses and Biological Activity of C-3′-Difluoromethyl-Taxoids. Bioorg. Med. Chem. 2000, 8, 1619-1628.
108. Ojima, I.; Wang, T.; Miller, M. L.; Lin, S.; Borella, C. P.; Geng, X.; Pera, P.; Bernacki, R. J. Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids. Bioorg. Med. Chem. Lett. 1999, 9, 3423-3428.
109. Ojima, I.; Kuduk, S. D.; Slater, J. C.; Gimi, R. H.; Sun, C. M. Syntheses of New Fluorine-Containing Taxoids by Means of β-Lactam Synthon Method. Tetrahedron 1996, 52, 209-224.
110. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22, 7280-7295.
111. Höfle, G.; Bedorf, N.; Gerth, K.; Reichenbach, H. (GFB). Epothilone derivatives. DE 4138042
112. Höfle, G.; Bedorf, N.; Steinmetz, H.; Schomburg, D.; Gerth, K.; Reichenbach, H. Epothilone A and B - Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567-1569.
113. Gerth, K.; Bedorf, N.; Höfle, g.; Irschik, H.; Reichenbach, H. J. Antibiotics 1996, 49, 560-563.
114. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M.; Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
115. Balog, A.; Meng, D.; Kamenecka, T.; Bertinato, P.; Su, D.-S.; Sorensen, E. J.; Danishefsky, S. J. Total Synthesis of (-)-Epothilone A. Angew. Chem. Int. Ed. Engl. 1996, 35, 2801-2803.
116. Yang, Z.; He, Y.; Vourloumis, D.; Vallberg, H.; Nicolaou, K. C. Total Synthesis of Epothilone A: The Olefin Metathesis Approach. Angew. Chem. Int. Ed. Engl. 1997, 36, 166-168.
117. Schinzer, D.; Limberg, A.; Bauer, A.; Böhm, O. M.; Cordes, M. Total Synthesis of (-)-Epothilone A. Angew. Chem. Int. Ed. Engl. 1997, 36, 523-524.
118. Nicolaou, K. C.; Roschanger, F.; Vourloumis, D. Chemical Biology of Epothilones. Angew. Chem. Int. Ed. Engl. 1998, 37, 2014-2045.
119. Harris, C. R.; Danishefsky, S. J. Complex Target-Oriented Synthesis in the Drug Discovery Process: A Case History in the dEpoB Series. J. Org. Chem. 1999, 64, 8434-8456.
120. Nettles, J. H.; Li, H.; Cornett, B.; Krahn, J. M.; Snyder, J. P. The Binding Mode of Epothilone A on α,β-Tubulin by Electron Crystallography. Science 2004, 305, 866-869.
121. Snyder, J. P.; Nettles, J. H.; Cornett, B.; Downing, K. H.; Nogales, E. The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5312-5316.
122. Heinz, D. W.; Schubert, W.-D.; Höfle, G. Much Anticipated - The Bioactive Conformation of Epothilone and its Binding to Tubulin. Angew. Chem. Int. Ed. Engl. 2005, 44, 1298-1301.
123. Kowalski, R. J.; Giannakakou, P.; Hamel, E. Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol). J. Biol. Chem. 1997, 272, 2534-2541.
124. Chou, T.-C.; Zhang, X.-G.; Balog, A.; Su, D.-S.; Meng, D.; Savin, K.; Bertino, J. R.; Danishefsky, S. J. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9642-9647.
125. Goodin, S.; Kane, M. P.; Rubin, E. H. Epothilones: Mechanism of Action and Biologic Activity. J. Clin. Oncol. 2004, 22, 2015-2025.
126. Nicolaou, K. C.; Ninkovic, S.; Finlay, M. R. V.; Sarabia, F.; Li, T. Total synthesis of 26-hydroxyepothilone B and related analogues. Chem. Commun. 1997, 2343-2344.
127. Nicolaou, K. C.; Finlay, M. R. V.; Ninkovic, S.; Sarabia, F. Total Synthesis of 26-Hydroxy-Epothilone B and Related Analogs via a Macrolactonization Based Strategy. Tetrahedron 1998, 54, 7127-7166.
128. Koch, G.; Loiseleur, O.; Altmann, K.-H. Total Synthesis of 26-Fluoro-epothilone B. Synlett 2004, 693-697.
129. Newman, R. A.; Yang, J.; Finlay, M. R. V.; Cabral, F.; Vourloumis, D.; Stefphens, L. C.; Troncoso, P.; Wu, X.; Logothetis, C. J.; Nicolaou, K. C.; Navone, N. M. Antitumor efficacy of 26-fluoroepothilone B against human prostrate cancer xenografts. Cancer Chemother. Pharmacol. 2001, 48, 319-326.
130. Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Chou, T.-C.; Doug, H.; Tong, W. P.; Danishefsky, S. J. Complex Target-Oriented Total Synthesis in the Drug Discovery Process: The Discovery of a Highly Promising Family of Second Generation Epothilones. J. Am. Chem. Soc. 2003, 125, 2899-2901.
131. Chao, T.-C.; Dong, H.; Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Cho, Y. S.; Tong, W. P.; Danishefsky, S. J. Design and Total Synthesis of a Superior Family of Epothilone Analogues, which Eliminate Xenograft Tumors to a Nonrelapsable State. Angew. Chem. Int. Ed. Engl. 2003, 42, 4762-4767.
132. Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Cho, Y. S.; Chou, T.-C.; Dong, H.; Danishefsky, S. J. Discovery of (E)-9,10-Dehydroepothilones through Chemical Synthesis: On the Emergence of 26-Trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a Promising Anticancer Drug Candidate. J. Am. Chem. Soc. 2004, 126, 10913-10922.
133. Chou, T.-C.; Dong, H.; Zhang, X.; Tong, W. P. Danishefsky, S. J. Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route. Cancer Res. 2005, 65, 9445-9454.